MYB (Ab-532) Antibody

What is MYB (Ab-532) Antibody and what specific epitope does it recognize?

MYB (Ab-532) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of total Myb protein. The antibody was developed against a synthesized non-phosphopeptide derived from human Myb protein, specifically targeting the region around the phosphorylation site of serine 532 (V-E-S(p)-P-T). This specificity makes it particularly valuable for studying Myb protein in its native state and examining phosphorylation-dependent functions .

The antibody recognizes Myb proto-oncogene protein (also known as C-myb), which corresponds to Swiss-Prot accession number P10242 and NCBI Gene ID 4602. The antibody is affinity-purified from rabbit antiserum using an epitope-specific immunogen to ensure high specificity .

What are the validated applications for MYB (Ab-532) Antibody in research settings?

The MYB (Ab-532) Antibody has been primarily validated for Western Blot (WB) applications. When using this antibody for Western blotting, researchers should expect to detect a band at approximately 80 kDa, which corresponds to the molecular weight of the Myb protein as determined by SDS-PAGE .

While the manufacturer specifically validates Western blotting, researchers should consider conducting preliminary validation experiments if attempting to use this antibody in other applications such as immunoprecipitation, immunohistochemistry, or flow cytometry. Similar polyclonal antibodies may work in these applications, but proper controls and optimization would be necessary.

What species reactivity has been confirmed for MYB (Ab-532) Antibody?

MYB (Ab-532) Antibody has been specifically validated to react with human Myb protein. The antibody was developed against a human-derived peptide sequence, so it shows highest specificity for human samples .

Cross-reactivity with Myb proteins from other species has not been explicitly confirmed in the provided information. Researchers working with non-human samples should perform validation experiments to confirm cross-reactivity with their species of interest, particularly if there is high sequence homology in the region containing serine 532.

What are the optimal storage and handling conditions to maintain MYB (Ab-532) Antibody activity?

For optimal performance, MYB (Ab-532) Antibody should be stored at -20°C. The antibody is supplied in a protective formulation consisting of rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

To maintain antibody performance:

• Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and loss of activity

• When removing from storage, thaw the antibody on ice

• Prepare working aliquots to minimize freeze-thaw cycles

• Return unused antibody to -20°C storage promptly

• Protect from extended exposure to room temperature

Similar to other antibody handling protocols, contamination should be avoided by using sterile technique when accessing the antibody solution.

How should researchers design validation experiments to confirm MYB (Ab-532) Antibody specificity in their experimental system?

When validating MYB (Ab-532) Antibody in a new experimental system, researchers should implement a multi-faceted approach:

• Positive and negative controls: Include cell lines or tissues known to express high levels of Myb protein (positive control) and those with minimal or no expression (negative control).

• Knockdown validation: Use siRNA or shRNA-mediated knockdown of MYB to demonstrate reduced signal intensity corresponding to decreased target protein.

• Overexpression validation: Complement with MYB overexpression experiments to demonstrate increased signal intensity.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to demonstrate signal abolishment if the antibody is specific.

• Signal correlation: Compare results with other validated anti-MYB antibodies recognizing different epitopes to confirm signal pattern consistency.

This comprehensive validation approach aligns with single-subject research validation principles, where multiple baselines and reversal designs can help establish causality and confirm specificity .

What is the recommended dilution range for MYB (Ab-532) Antibody in Western blot applications?

While the search results do not provide a specific recommended dilution for this particular antibody, the concentration of the antibody is 1.0mg/ml . Based on standard protocols for polyclonal antibodies of similar concentration:

Recommended dilution ranges for Western blot applications:

Researchers should perform a dilution series to determine the optimal concentration for their specific experimental conditions. Factors affecting optimal dilution include:

• Sample type (cell lysate, tissue homogenate)

• Protein expression level

• Detection method (chemiluminescence, fluorescence)

• Blocking reagent used

It is recommended to start with the middle range (1:1000) and adjust based on signal-to-noise ratio in preliminary experiments.

How does phosphorylation status at Ser532 affect MYB (Ab-532) Antibody binding and what are the implications for studying MYB signaling pathways?

MYB (Ab-532) Antibody was generated against a non-phosphopeptide derived from human Myb around the phosphorylation site of serine 532 (V-E-S(p)-P-T) . This has significant implications for studying MYB signaling pathways:

For comprehensive phosphorylation studies, researchers might consider employing:

• Phospho-specific MYB antibodies (if available)

• Lambda phosphatase treatment of samples to remove phosphorylation

• Complementary techniques like mass spectrometry to confirm phosphorylation status

Understanding the phosphorylation dynamics at Ser532 is particularly relevant because:

• Phosphorylation often regulates transcription factor activity

• It may impact protein-protein interactions in signaling cascades

• It could affect protein stability and turnover

What experimental approaches are recommended when using MYB (Ab-532) Antibody to investigate protein-protein interactions involving MYB?

When investigating protein-protein interactions involving MYB using MYB (Ab-532) Antibody, researchers should consider these methodological approaches:

Co-immunoprecipitation (Co-IP) strategy:

• Use MYB (Ab-532) Antibody for immunoprecipitation of MYB protein complexes

• Perform Western blot analysis of the precipitate using antibodies against suspected interaction partners

• Include appropriate controls (IgG control, input control)

• Consider crosslinking to stabilize transient interactions

Proximity Ligation Assay (PLA) approach:

• Use MYB (Ab-532) Antibody in combination with antibodies against potential interaction partners

• Implement proper controls to validate interaction specificity

• Quantify interaction signals across different experimental conditions

Analytical considerations:

• Perform stringent washing steps to minimize non-specific binding

• Consider native versus denaturing conditions based on the nature of the interaction

• Validate interactions using complementary approaches (e.g., GST pull-down, yeast two-hybrid)

How can MYB (Ab-532) Antibody be integrated into ChIP-seq experiments to study MYB transcriptional networks?

Integrating MYB (Ab-532) Antibody into Chromatin Immunoprecipitation sequencing (ChIP-seq) experiments requires careful methodological consideration:

Optimization strategy for ChIP-seq application:

• Crosslinking optimization: Test different formaldehyde concentrations (0.75-1.5%) and incubation times (5-15 minutes) to preserve protein-DNA interactions without overfixing

• Sonication parameters: Optimize sonication conditions to achieve DNA fragments between 200-500 bp

• Antibody validation: Perform preliminary ChIP-qPCR targeting known MYB binding sites

• Immunoprecipitation conditions: Determine optimal antibody concentration and incubation time

Critical quality control measures:

• Verify enrichment at known MYB target genes using qPCR prior to sequencing

• Include appropriate controls (IgG control, input control)

• Validate findings with orthogonal methods (e.g., reporter assays)

Data analysis framework:

• Identify MYB binding sites genome-wide using peak calling algorithms

• Perform motif analysis to confirm enrichment of MYB consensus binding sequences

• Integrate with gene expression data to identify direct MYB targets

• Conduct pathway analysis to understand biological functions of MYB-regulated genes

This methodical approach to experimental design ensures reliable identification of MYB transcriptional networks, similar to how multiple-baseline designs across settings can provide robust evidence for intervention effects .

What are common technical challenges when using MYB (Ab-532) Antibody in Western blotting and how can they be addressed?

Researchers working with MYB (Ab-532) Antibody may encounter several technical challenges in Western blotting applications. Here are evidence-based solutions:

Challenge: High background signal

• Solution: Increase blocking stringency (5% BSA instead of milk, longer blocking time)

• Implement more stringent washing steps (increased TBST concentration, additional washes)

• Optimize antibody dilution (try more dilute antibody solution)

• Use fresh blocking reagents and buffers

Challenge: Weak or absent signal

• Solution: Increase protein loading (up to 50-75 µg total protein)

• Reduce antibody dilution (try 1:500 instead of 1:1000)

• Extend primary antibody incubation (overnight at 4°C)

• Verify target protein expression in your sample

• Ensure transfer efficiency with reversible protein stain

Challenge: Multiple bands/non-specific binding

• Solution: Increase antibody dilution (1:2000-1:5000)

• Optimize blocking conditions (try different blocking agents)

• Include competitive peptide control

• Consider gradient gels for better resolution

Challenge: Inconsistent results

• Solution: Standardize lysate preparation methods

• Implement quality control for protein quantification

• Maintain consistent experimental conditions

• Consider using internal loading controls for normalization

These troubleshooting approaches follow principles similar to the visual inspection methods used in single-subject research designs, where researchers systematically modify conditions to achieve stable and interpretable results .

How do sample preparation methods affect MYB (Ab-532) Antibody detection sensitivity and what optimization steps are recommended?

Sample preparation significantly impacts MYB (Ab-532) Antibody detection sensitivity. The following optimizations are recommended:

Lysis buffer composition optimization:

Sample handling protocol:

• Harvest cells/tissues rapidly and process immediately or flash-freeze

• Maintain samples at cold temperatures throughout processing

• Sonicate briefly to shear DNA and reduce sample viscosity

• Centrifuge at high speed (14,000 × g, 15 min) to remove cellular debris

• Quantify protein concentration using a detergent-compatible assay

Denaturation considerations:

• Standard denaturation (95°C, 5 min in Laemmli buffer with β-mercaptoethanol) is usually sufficient

• For membrane-associated proteins, consider gentler denaturation (70°C, 10 min)

• Include both denatured and non-denatured samples in validation experiments

Sample storage:

• Prepare single-use aliquots to avoid freeze-thaw cycles

• Store at -80°C for long-term preservation

• Add additional protease inhibitors if samples must be stored before analysis

This systematic approach to sample preparation optimization is similar to establishing baseline conditions in single-subject research designs, where stable conditions are necessary before experimental manipulations .

How can researchers differentiate between splice variants and post-translational modifications of MYB when interpreting Western blot results with MYB (Ab-532) Antibody?

Differentiating between splice variants and post-translational modifications (PTMs) of MYB requires a strategic analytical approach:

Analytical strategy for variant identification:

• Molecular weight analysis: Compare observed band sizes with predicted molecular weights of known MYB splice variants (typically ranging from 72-89 kDa)

• Cell/tissue type context: Consider known expression patterns of MYB variants in your experimental system

• Treatment effects: Observe how band patterns change with treatments known to affect specific PTMs (e.g., phosphatase treatment)

Experimental validation approaches:

• RNA analysis: Perform RT-PCR with splice variant-specific primers to confirm expression of specific MYB isoforms

• Mass spectrometry: Use targeted proteomics to identify specific peptides unique to variants or PTMs

• Comparison with isoform-specific antibodies: Use antibodies targeting specific MYB variants in parallel experiments

• Engineered expression systems: Express individual MYB variants in a controlled system to establish migration patterns

Methodological recommendations for PTM assessment:

• Phosphorylation analysis: Treat samples with lambda phosphatase to identify shifts due to phosphorylation

• Ubiquitination assessment: Use deubiquitinating enzymes and observe molecular weight shifts

• Glycosylation evaluation: Treat with glycosidases to identify glycosylated forms

Interpretation framework:

• Bands between 75-85 kDa likely represent different phosphorylation states of full-length MYB

• Bands below 75 kDa may indicate proteolytic cleavage or shorter splice variants

• Bands above 85 kDa could suggest ubiquitination or other large PTMs

This methodical approach to data interpretation is analogous to the careful analysis of multiple variables in single-subject research, where distinguishing between different causes of behavioral changes requires systematic investigation .

How does MYB (Ab-532) Antibody compare with other commercially available MYB antibodies in terms of specificity and research applications?

When selecting between different MYB antibodies for research, investigators should consider several comparative factors:

Antibody comparison matrix:

Application-specific considerations:

• For isoform-specific detection, monoclonal antibodies targeting unique regions may be preferable

• For studies requiring detection of all MYB forms, polyclonal antibodies like MYB (Ab-532) offer broader detection

• For techniques requiring high reproducibility across experiments, monoclonal antibodies may provide more consistent results

What strategies can be employed to integrate MYB (Ab-532) Antibody detection with other -omics approaches for comprehensive MYB functional studies?

Integrating antibody-based detection with multi-omics approaches creates a more comprehensive understanding of MYB function:

Multi-omics integration framework:

• Genomics integration: Correlate MYB protein levels (detected by MYB (Ab-532) Antibody) with genomic variants in the MYB gene or regulatory regions

• Transcriptomics correlation: Compare MYB protein expression patterns with MYB mRNA levels across different conditions

• Proteomics extension: Use MYB (Ab-532) Antibody for immunoprecipitation followed by mass spectrometry to identify MYB interactome

• Epigenomics connection: Combine ChIP-seq using MYB (Ab-532) Antibody with histone modification profiling to understand chromatin context of MYB binding

Methodological workflow for integrated analysis:

• Use consistent sample preparation methods across platforms

• Implement synchronized experimental timing to capture dynamic processes

• Employ appropriate statistical methods for multi-omics data integration

• Validate key findings with orthogonal techniques

Analytical considerations:

• Address different data scales and normalization requirements

• Consider temporal dynamics when integrating datasets

• Implement advanced computational methods (network analysis, machine learning algorithms)

• Validate computational predictions with focused biological experiments

This integrated approach to multi-omics data analysis is conceptually similar to multiple-baseline designs across different variables in single-subject research, where examining multiple outcomes provides more comprehensive evidence of intervention effects .

How should researchers design experiments to investigate potential cross-reactivity of MYB (Ab-532) Antibody with other MYB family members (A-MYB, B-MYB)?

MYB family proteins share structural similarities that necessitate careful experimental design to assess potential cross-reactivity:

Sequence alignment analysis:
The first step is to perform in silico analysis of sequence homology between the peptide used to generate MYB (Ab-532) Antibody and corresponding regions in A-MYB and B-MYB. Regions with high homology may indicate potential cross-reactivity.

Experimental validation protocol:

• Overexpression system: Express each MYB family member individually in a cell line with minimal endogenous expression

• Knockdown validation: Perform selective knockdown of each family member to observe changes in antibody detection pattern

• Peptide competition: Use peptides derived from each family member in competition assays

• Recombinant protein analysis: Test antibody against purified recombinant MYB family proteins

Analytical approach:

Interpretation framework:

• Compare observed molecular weights with predicted values for each family member

• Consider tissue-specific expression patterns of MYB family members when selecting experimental systems

• Validate findings with family member-specific antibodies as positive controls

This systematic approach to cross-reactivity assessment parallels the methodology used in multiple-treatment reversal designs, where careful manipulation of individual variables allows researchers to distinguish between different causal factors .